Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography

Overview

Migraine affects 16% of the world population and is one of the most disabling of all disorders. It is a complex brain disorder characterized primarily by recurrent headache attacks. The signaling molecule serotonin (5-hydroxytryptamine, 5-HT) has for decades been thought to play a central role in migraine pathophysiology. The most effective class of abortive migraine drugs, the triptans, act on 5-HT receptors. However, the migraine-specific actions of serotonin and the mechanisms of triptans are still unknown. In this project the investigators will use high-resolution positron emission tomography and specific radioligands to investigate the significance of serotonin in migraine. Two newly developed radioligands that are specific for the 5-HT1B and 5-HT4 receptor, respectively, will be applied. To investigate the level and distribution of serotonin in the migraine brain the investigators will compare the binding of these ligands in episodic migraine patients with healthy controls. In addition, the investigators will include chronic migraine patients to evaluate the relation between the level of serotonin in the brain and the frequency of migraine attacks. To investigate the changes in the serotonin level during a migraine attack and the effects of triptans on the central nervous system the investigators will repeat the scans using the 5-HT1B specific ligand during induced migraine attacks and following treatment with sumatriptan. The results from this study will shed light on the role of serotonin in the migraine brain and elucidate the migraine-specific action of triptans. This will improve our understanding of the migraine pathophysiology and, potentially, facilitate the development of more efficient treatment of migraine.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: August 2017

Interventions

  • Other: PET scan with 5-HT receptor ligands
    • Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.

Arms, Groups and Cohorts

  • Migraine without aura
    • Migraine patients suffering from migraine 0-4 days per month.
  • Healthy controls
    • Healthy controls with no history of migraine or other primary headaches.
  • Chronic migraine
    • Migraine patients with chronic migraine

Clinical Trial Outcome Measures

Primary Measures

  • Differences in binding of the 5-HT1B radioligand
    • Time Frame: Up to 1 year
    • Differences in bindingpotentials for the 5-HT1B ligand between migraine patients and healthy controls will be assessed using the Simplified Reference Tissue Model.
  • Differences in binding of the 5-HT4 radioligand
    • Time Frame: Up to 1 year
    • Differences in bindingpotentials for the 5-HT4 ligand between migraine patients and healthy controls will be assessed using the Simplified Reference Tissue Model.
  • Differences in binding of the 5-HT4 radioligand
    • Time Frame: Up to 1 year
    • Differences in bindingpotentials for the 5-HT4 ligand between chronic migraine patients and healthy controls and between chronic and episodic migraine patients will be assessed using the Simplified Reference Tissue Model.
  • Correlation with migraine frequency and 5-HT4 receptor binding
    • Time Frame: Up to 1 year
    • Correlations between migraine days and 5-HT4 receptor binding will be investigated using pooled data from episodic and chronic migraine patients on migraine frequency and their 5-HT4 receptor binding potentials assessed using the simplified reference tissue model
  • Differences in binding of the 5-HT1B radioligand
    • Time Frame: Up to 1 year
    • Differences in binding between ictal and interictal binding and between ictal and post-treatment binding in episodic migraine patients will be assessed using the simplified reference tissue model

Participating in This Clinical Trial

Inclusion Criteria, both groups: • Written informed consent Inclusion Criteria, episodic migraine patients:

  • Migraine without aura according to the International Headache Society (IHS) 0-4 days per month – The migraine is treatable with sumatriptan Inclusion Criteria, chronic migraine patients: Fulfill IHS criteria for chronic migraine Inclusion Criteria, healthy controls: – Do not suffer from migraine according to IHS – Do not have any first degree relatives with migraine Exclusion Criteria:

  • Tension type headache more than 5 days per month during the last year. – Tension type headache on the experimental day. – Any other primary headache disorder – Migraine 48 hour before and after the experimental day (only episodic migraine patients) – Use of antimigraine medication or pain-killer on the experimental day before PET – Pregnant or breastfeeding women. – Contraindications against MRI. – History or clinical sign of cardio- or cerebrovascular disease. – Untreated severe mental disorder or drug abuse. – Other diseases or disorders interpreted, by the examining doctor, to interfere with participation in the study. – Not accepting information about potential accidental findings during the experiment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Danish Headache Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Marie Deen Christensen, Medical Doctor – Danish Headache Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.